Drugs / Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01529645 | Mar → Jul 2012 | diphtheria, pertussis, tetanus | Novartis Vaccines | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01529645 ↗ |
| Known as | TdaP | “Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's...” NCT01529645 ↗ |
| Modality | Vaccine | “Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's...” NCT01529645 ↗ |
| Route | Intramuscular | “administered with different antigen doses intramuscularly in the upper deltoid region” NCT01529645 ↗ |